Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Ursodeoxycholic Acid to Prevent Radiation Dermatitis in Breast Cancer Radiotherapy
ChiCTR2400085925Phase 2Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ursodeoxycholic acid in radiodermatitis (2 arms), sponsored by Mianyang Central Hospital. Primary endpoints: Incidence of radiation-induced dermatitis grade ≥2 (Phase II) and Therapeutic toxicity of ursodeoxycholic acid (Phase I). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on ChiCTR2400085925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085925.